{
    "root": "3d02b630-f667-47e6-b2d5-f7317b73df2e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Doxorubicin Hydrochloride",
    "value": "20250410",
    "ingredients": [
        {
            "name": "DOXORUBICIN HYDROCHLORIDE",
            "code": "82F2G7BL4E"
        },
        {
            "name": "HYDROGENATED SOYBEAN LECITHIN",
            "code": "H1109Z9J4N"
        },
        {
            "name": "SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
            "code": "3L6NN8ZZKU"
        },
        {
            "name": "CHOLESTEROL",
            "code": "97C5T2UQ7J"
        },
        {
            "name": "AMMONIUM SULFATE",
            "code": "SU46BAM238"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "Doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy (1.1). AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy (1.2). Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy (1.3).",
    "contraindications": "Administer doxorubicin hydrochloride liposome injection at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution (2). Ovarian cancer: 50 mg/m 2 intravenously every 4 weeks (2.2) AIDS-related Kaposi’s Sarcoma: 20 mg/m 2 intravenously every 3 weeks (2.3) Multiple Myeloma: 30 mg/m 2 intravenously on day 4 following bortezomib (2.4)",
    "warningsAndPrecautions": "Doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10 mL or 25 mL glass, single-dose vials.\n                      The following individually cartoned vials are available:\n                  \n                     \n                  \n                  \n                     Table 14 \n                     \n                        \n                           mg in vial\n                           fill volume\n                           vial size\n                           NDC #s\n                        \n                        \n                           20 mg vial\n                           10 mL\n                           10 mL\n                           72603-103-01\n                        \n                        \n                           50 mg vial\n                           25 mL\n                           30 mL\n                           72603-200-01\n                        \n                     \n                  \n                  \n                  Refrigerate unopened vials of doxorubicin hydrochloride liposome injection at 2° to 8°C (36° to 46°F). Do not freeze. Discard unused portion. Doxorubicin hydrochloride liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures1.",
    "adverseReactions": "Doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2)]."
}